{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:39:28Z","timestamp":1784651968805,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"national institute of allergy and infectious diseases","doi-asserted-by":"publisher","award":["K01AI148583"],"award-info":[{"award-number":["K01AI148583"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"johns hopkins alliance for a healthier world","award":["80045453"],"award-info":[{"award-number":["80045453"]}]},{"name":"stop tb partnership tb reach","award":["134126"],"award-info":[{"award-number":["134126"]}]},{"name":"the pittsfield anti-tb association","award":["80042621"],"award-info":[{"award-number":["80042621"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Although individual antiretroviral drugs have been shown to be associated with elevated cardiovascular disease (CVD) risk, data are limited on the role of antiretroviral drug combinations. Therefore, we sought to investigate CVD risk associated with antiretroviral drug combinations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using an administrative health-plan dataset, risk of acute myocardial infarction (AMI) associated with current exposure to antiretroviral drug combinations was assessed among persons living with HIV receiving antiretroviral therapy (ART) across the U.S. from October 2009 through December 2014. To account for confounding-by-indication and for factors simultaneously acting as causal mediators and confounders, we applied inverse probability of treatment weighted marginal structural models to longitudinal data of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Over 114,417 person-years (n\u2009=\u200973,071 persons) of ART exposure, 602 cases of AMI occurred at an event rate of 5.26 (95% CI: 4.86, 5.70)\/1000 person-years. Of the 14 antiretroviral drug combinations studied, persons taking abacavir-lamivudine-darunavir had the highest incidence rate (IR: 11\/1000; 95% CI: 7.4\u201316.0) of AMI. Risk (HR; 95% CI) of AMI was elevated for current exposure to abacavir-lamivudine-darunavir (1.91; 1.27\u20132.88), abacavir-lamivudine-atazanavir (1.58; 1.08\u20132.31), and tenofovir-emtricitabine-raltegravir (1.35; 1.07\u20131.71). Tenofovir-emtricitabine-efavirenz was associated with reduced risk (0.65; 0.54\u20130.78). Abacavir-lamivudine-darunavir was associated with increased risk of AMI beyond that expected of abacavir alone, likely attributable to darunavir co-administration. We did not find an elevated risk of AMI when abacavir-lamivudine was combined with efavirenz or raltegravir.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The antiretroviral drug combinations abacavir-lamivudine-darunavir, abacavir-lamivudine-atazanavir and tenofovir-emtricitabine-raltegravir were found to be associated with elevated risk of AMI, while tenofovir-emtricitabine-efavirenz was associated with a lower risk. The AMI risk associated with abacavir-lamivudine-darunavir was greater than what was previously described for abacavir, which could suggest an added risk from darunavir. The results should be confirmed in additional studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-021-00383-7","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T11:04:58Z","timestamp":1630926298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States"],"prefix":"10.1186","volume":"18","author":[{"given":"Kunchok","family":"Dorjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsering","family":"Choden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv M.","family":"Baxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan E.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur L.","family":"Reingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"383_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics\u20142020 fact sheet. 2020. https:\/\/www.unaids.org\/en\/resources\/fact-sheet#:~:text=38.0%20million%20%5B31.6%20million%E2%80%9344.5,AIDS%2Drelated%20illnesses%20in%202019. Accessed 12 Nov 2018."},{"issue":"1","key":"383_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/cid\/cit196","volume":"57","author":"M Rotger","year":"2013","unstructured":"Rotger M, Glass TR, Junier T, et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis. 2013;57(1):112\u201321.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"383_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/QAI.0000000000001642","volume":"78","author":"RA Elion","year":"2018","unstructured":"Elion RA, Althoff KN, Zhang J, et al. Recent abacavir use increases risk of type 1 and type 2 myocardial infarctions among adults with HIV. J Acquir Immune Defic Syndr. 2018;78(1):62\u201372.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"383_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/QAI.0000000000000881","volume":"71","author":"JL Marcus","year":"2016","unstructured":"Marcus JL, Neugebauer RS, Leyden WA, et al. Use of abacavir and risk of cardiovascular disease among HIV-infected individuals. J Acquir Immune Defic Syndr. 2016;71(4):413\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"383_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12879-017-2808-8","volume":"17","author":"K Dorjee","year":"2017","unstructured":"Dorjee K, Baxi SM, Reingold AL, Hubbard A. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. BMC Infect Dis. 2017;17(1):708.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"383_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ijantimicag.2018.07.010","volume":"52","author":"K Dorjee","year":"2018","unstructured":"Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analyses of results from seventeen epidemiologic studies. Int J Antimicrob Agents. 2018;52(5):541\u201353.","journal-title":"Int J Antimicrob Agents"},{"key":"383_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12916-016-0588-4","volume":"14","author":"CA Sabin","year":"2016","unstructured":"Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med. 2016;14:61.","journal-title":"BMC Med"},{"issue":"9622","key":"383_CR8","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","volume":"371","author":"CA Sabin","year":"2008","unstructured":"Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417\u201326.","journal-title":"Lancet"},{"issue":"3","key":"383_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/cid\/civ316","volume":"61","author":"M Desai","year":"2015","unstructured":"Desai M, Joyce V, Bendavid E, et al. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis. 2015;61(3):445\u201352.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"383_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40268-018-0238-8","volume":"18","author":"M Opsomer","year":"2018","unstructured":"Opsomer M, Dimitrova D, Verspeelt J, et al. Evaluation of cardiovascular disease risk in HIV-1-infected patients treated with darunavir. Drugs R D. 2018;18(3):199\u2013210.","journal-title":"Drugs R D"},{"issue":"6","key":"383_CR11","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","volume":"5","author":"L Ryom","year":"2018","unstructured":"Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A: D international prospective multicohort study. Lancet HIV. 2018;5(6):e291\u2013300.","journal-title":"Lancet HIV"},{"issue":"12","key":"383_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41569-019-0219-9","volume":"16","author":"PY Hsue","year":"2019","unstructured":"Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol. 2019;16(12):745\u201359.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"383_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/cid\/cir269","volume":"53","author":"RJ Bedimo","year":"2011","unstructured":"Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53(1):84\u201391.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"383_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/EDE.0000000000000041","volume":"25","author":"ES Brouwer","year":"2014","unstructured":"Brouwer ES, Napravnik S, Eron JJ Jr, et al. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. Epidemiology. 2014;25(3):406\u201317.","journal-title":"Epidemiology"},{"issue":"4","key":"383_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/QAI.0000000000000662","volume":"69","author":"J Young","year":"2015","unstructured":"Young J, Xiao Y, Moodie EEM, et al. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2015;69(4):413\u201321.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"383_CR16","unstructured":"IQVIA. IMS health pharmetrics plus data dictionary. 2013. https:\/\/tri.uams.edu\/wp-content\/uploads\/sites\/80\/2015\/08\/Pharmetrics-Plus-Data-Dictionary-Jan-2013.pdf. Accessed 19 Jul 2020."},{"key":"383_CR17","unstructured":"Centers for Disease Control and Prevention. HIV-Positive !dults in are in the United States, Medical Monitoring Project, 2009\u20132014. 2014. https:\/\/www.cdc.gov\/hiv\/pdf\/statistics\/systems\/mmp\/cdc-hiv-mmp-national-data-2009-2014.pdf. Accessed 19 Jul 2020"},{"issue":"5","key":"383_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550\u201360.","journal-title":"Epidemiology"},{"issue":"6","key":"383_CR19","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656\u201364.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"383_CR20","first-page":"402","volume":"4","author":"Z Fewell","year":"2004","unstructured":"Fewell Z, Hernan MA, Wolfe F, Tilling K, Choi H, Sterne JAC. Controlling for time-dependent confounding using marginal structural models. Stand Genomic Sci. 2004;4(4):402\u201320.","journal-title":"Stand Genomic Sci"},{"issue":"12","key":"383_CR21","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67\u2013492.","journal-title":"Circulation"},{"issue":"2","key":"383_CR22","doi-asserted-by":"publisher","first-page":"ofw061","DOI":"10.1093\/ofid\/ofw061","volume":"3","author":"L Rosenblatt","year":"2016","unstructured":"Rosenblatt L, Farr AM, Johnston SS, Nkhoma ET. Risk of Cardiovascular events among patients initiating efavirenz-containing versus efavirenz-free antiretroviral regimens. Open Forum Infect Dis. 2016;3(2):ofw061.","journal-title":"Open Forum Infect Dis"},{"issue":"9712","key":"383_CR23","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","volume":"375","author":"JJ Eron","year":"2010","unstructured":"Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396\u2013407.","journal-title":"Lancet"},{"issue":"1","key":"383_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","volume":"55","author":"JL Lennox","year":"2010","unstructured":"Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55(1):39\u201348.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"383_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1179\/1945577115Y.0000000002","volume":"16","author":"L Young","year":"2015","unstructured":"Young L, Wohl DA, Hyslop WB, Lee YZ, Napravnik S, Wilkin A. Effects of raltegravir combined with tenofovir\/emtricitabine on body shape, bone density, and lipids in African\u2013Americans initiating HIV therapy. HIV Clin Trials. 2015;16(5):163\u20139.","journal-title":"HIV Clin Trials"},{"issue":"3","key":"383_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/cid\/civ296","volume":"61","author":"JR Santos","year":"2015","unstructured":"Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(3):403\u20138.","journal-title":"Clin Infect Dis"},{"issue":"14","key":"383_CR27","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1097\/QAD.0b013e32833d2132","volume":"24","author":"JA Delaney","year":"2010","unstructured":"Delaney JA, Scherzer R, Biggs ML, et al. Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS. 2010;24(14):2201\u20139.","journal-title":"AIDS"},{"issue":"2","key":"383_CR28","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","volume":"140","author":"MJ Feinstein","year":"2019","unstructured":"Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140(2):e98\u2013124.","journal-title":"Circulation"},{"issue":"13","key":"383_CR29","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1097\/QAD.0000000000001590","volume":"31","author":"L Elzi","year":"2017","unstructured":"Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31(13):1853\u20138.","journal-title":"AIDS"},{"key":"383_CR30","unstructured":"U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. October 25, 2018 2018. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/11\/what-to-start--initial-combination-regimens-for-the-antiretroviral-naive-patient. Accessed 12 Nov 2018."},{"issue":"1","key":"383_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","volume":"148","author":"Y Kiyota","year":"2004","unstructured":"Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99\u2013104.","journal-title":"Am Heart J"},{"issue":"5","key":"383_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","volume":"11","author":"MA Hernan","year":"2000","unstructured":"Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561\u201370.","journal-title":"Epidemiology"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00383-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-021-00383-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00383-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T11:19:04Z","timestamp":1630927144000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-021-00383-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["383"],"URL":"https:\/\/doi.org\/10.1186\/s12981-021-00383-7","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"16 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Committee for Protection of Human Subjects at the University of California, Berkeley as non-human subjects research, obviating the need for participant consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to report for any author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}